co
kstew call note focu lower guidanc
confid acceler
share bit pressur morn dow versu dow et
surpris move quarter report morn bit mix ith revenu come littl light manag cite
distributor inventori adjust time though ep ahead street believ reaction due
reduct ep guidanc hich like street expect guidanc reduc drug-coat
balloon hich believ somew hat expect ell fx hich believ expect
note bd earn call focu call expect revis outlook manag reduc
guidanc morn reflect increment fx headw ind ell headw ind drug coat balloon dcb result
fda letter issu march here coupl point call
perform manag note ep line ith expect manag comment revenu grew
compar constant currenc basi ere tw item brought revenu slightli bd
expect first medic deliveri solut us impact distributor inventori adjust
hypoderm busi ith manag note inventori level ere normal expect strong demand rest
year second result impact dcb busi specif fda mid-march updat
guidanc updat manag maintain overal compar constant currenc grow th rate ever
call manag said believ low er end rang like given chang expect bd intervent
dcb expect bdi grow vs prior manag assum dcb busi
declin remaind year note rate experienc late-march month
april also assum receiv knee btk indic year rather bd expect approv next year
though remain discuss ith fda note fda advisori meet june could potenti chang
trajectori dcb busi depend outcom model alreadi incorpor dcb headw ind
model around reduct sale similar hat bd guidanc reflect ere expect
compar constant currenc grow th ould around low end guidanc updat fairli consist ith
 hat ere think manag note sever time call confid abil deliv acceler
perform
outlook manag comment earli provid guidanc manag discuss
underli perform remain strong despit face near-term headw ind note fx pressur eigh
year perform abat next year note gore royalti rate run higher level origin
expect manag note bard deal model cost synergi track expect achiev cost
synergi model street believ compani off-set gore royalti
headw ind assum continu impact dcb ep estim today releas
stood versu street ep estim also street versu street
 incorpor headw ind dcb reflect increment fx headw ind enough
swatch delay manag note receiv feedback fda diabet type patch product sw atch
 current review ing/assess implic manag note feedback comprehens
expect given bd consid varieti option strategi expect launch delay bd plan provid
updat program august next call
rest note im san francisco heart rhythm societi meet best ay reach via email
 head time year againinstitut investor survey vote season want express ii
import import barclay would appreci support vote medic suppli devic
categori dont feel ive earn vote pleas let know futur
result includ non-cash charg period relat product liabil matter relat certain legaci bard
surgic product also april notifi custom recal expans pump includ pump ith certain mold
compon manufactur betw een april record cumul charg relat recal
effort expect remedi ill occur next year
revenu grow th rate mention compar constant currenc basi
confid bd strategi ork core remain strong bd continu invest innov
perform broadli line ith expect solid perform core combin ith continu focu drive
oper effici bard cost synergi
compar constant currenc revenu grow th ep line ith guidanc rang result right
manag expect expect grow th full year guidanc rang expect strong
underli core busi grow th off-set tough flu comparison time ithin pharm system busi tw addit
factor impact grow th quarter market reaction fda letter regard drug coat balloon dcb time
medic deliveri solut busi us hen factor item underli revenu grow th line ith
remain pleas ith integr bard track cost revenu synergi captur target gain momentum
invest made last year progress system integr suppli chain initi
updat ep guidanc hich reflect strong underli perform partial off-set headw ind dcb busi ell
addit fx pressur due broad strengthen us dollar manag confid back half acceler
revenu grew compar constant currenc basi revenu broadli line ith expect driven strong
underli core busi ere item brought revenu slightli bd expect first medic
deliveri solut us impact distributor inventori adjust hypoderm busi inventori level
normal expect strong demand rest year second result impact dcb busi fda mid-march
adjust ep fxn fx neutral basi line ith previous commun expect
continu de-lev paid dow debt track de-lev year
bd medic revenu increas revenu medic deliveri solut ere reflect tough comp
prior year us inventori adjust impact grow th quarter bd expect strong demand grow th busi
ou grow th md driven strength europ across vascular access manag vascular access devic
medic manag solut revenu ere ith grow th driven strong infus strength retail
dispens diabet sale ere expect rebound low er grow th strength us ou aid
time order pharma system sale grew reflect time custom order hich benefit neg
bd lifesci grew quarter headw ind last year flu season diagnost system sale
 ere dow ith headw ind tough flu underli perform solid doubl digit grow th bd max
preanalyt solut revenu ere grow th aid capac addit improv suppli push button
expect partial offset time distributor order benefit bioscienc grow th driven
research reagent facssymphoni facslyr platform strength emerg market
bd intervent reflect unfavor impact hurrican dcb underli basi grow th
peripher intervent reflect impact dcb busi underli basi pi sale ere driven global
grow th end stage renal diseas emerg market surgeri grow th reflect tough comp hernia hen releas
suppli backord follow ing hurrican strong biosurgeri infect prevent continu benefit revenu synergi
invest urolog critic ucc driven acut urolog strength home care target temperatur
revenu region
us normal grow th rate due dcb distributor inventori adjust ell tough flu comparison
ou solid three segment ith strength emerg market strength europ develop market grow th
 reflect solid europ partial off-set us emerg market driven china doubl digit grow th
revenu compar basi
gross profit exclud impact fx gross profit margin quarter perform basi flat y/i line ith
expect margin improv driven continu improv initi cost synergi off-set unfavor mix driven
low er flu dcb ell headw ind raw materi price fx neg hich greater anticip
due strengthen us dollar vs currenc
ssg reflect defer compens expens quarter fulli off-set incom off-set
harmon time ith bard comp plan expect underli basi expens grow ing slow er sale
reflect on-going cost disciplin achiev bard cost synergi
 reflect continu commit innov
oper margin dow cc basi line ith manag expect decreas driven increas ssg
quarter
tax rate quarter line ith expect high end guidanc rang
prefer share dividend
ep dow y/i fxn basi
underli perform strong expect look number driver give
confid acceler share gain revenu synergi captur md continu strong grow th bd max time
instrument sale reagent bioscienc bd intervent launch sever new product perform anticip
expect product launch bd expect continu doubl digit grow th china
expect revenu grow th bd intervent due dcb headw ind re-affirmed total compani updat
guidanc reflect reduct dcb sale remaind year continu expect bd medic sale grow
lifesci grow th bd expect emerg market grow th driven low doubl digit grow th china
strength emea latin america
expect report revenu grow th due increment fx pressur
ep guidanc reflect continu strong underli perform driven revenu grow th oper margin perform
off-set near term headw ind constant currenc basi expect ep grow th reflect headw ind
approxim relat dcb expect currenc addit headw ind current forecast euro rate vs
expect updat forecast also reflect increment pressur attribut profit inventori bd expect
deliv adjust ep
magnitud headw ind bd face year significantli greater recent year total headw ind
bd abil off-set year hich greater compani abl off-set
past year
integr bard much track togeth even greater abil off-set headw ind drive robust
 forecast updat reflect headw ind dcb fx expect report revenu grow th due increment
fx pressur gross margin expect oper margin margin
approxim low er previou guidanc due dcb fx headw ind oper cash flow expect
balanc guidanc remain unchang
continu expect achiev cost synergi year track fulli realiz three year deal period
feel good momentum across busi
continu rich pipelin
adopt new alari pump aid strong grow th infus healthsight platform gain good feedback diabet care
see good uptak new nano pen needl md launch tw new product pow er glide bd vena picc
regard type patch pump recent receiv feedback process evalu respond
feedback receiv comprehens expect given fda comment bd consid varieti option
strategi expect launch delay bd plan provid updat august next call
lifesci clearanc bd facduet facslryic
intervent clearanc avelinq also approv venovo venou stent
solid across core region right thought ould bard integr ontrack driver across segment
give confid acceler
revenu guidanc assum reduct dcb think rate right reduct hat bd
project remaind year hat bd see late march end april right bd call
experienc talk fda btk assum btk launch next fiscal year ell hen take
impact guidanc rang bring dow low end guidanc
think action take off-set headwind longer term growth outlook consid
royalti come bd drive underli grow th come y/i tax rate grow th
abl grow th past fxn ep grow th expect despit pressur
abil drive good strong fxn grow th despit pressur bd plan stage
disciplin expens manag across board sell market ell continu manag
line bd look drive effici program across organ substanti progress year paclitaxel dig
becom confid safeti lutonix look forw ard fda discuss june bd
restructur organ point time bd go hire btk launch bd ill monitor come
fda session make decis bd still activ discuss ith fda btk product uniqu product
there valid treatment option beyond amput manag comment approv may ill
later everyth off-set headw ind taken dcb data third parti analysi us
feel good safeti result
fx guidanc top line impact currenc top ep hit ratio
greater fx estim impact new guidanc seen sinc novemb strengthen dollar vs euro
currenc alreadi experienc pressur slightli ors expect expect fx pressur
expect ors expect thought turn around dont think ill happen
neutral off-set rel flat profit inventori impact lessen one thing
consid ith drop hen pressur come currenc euro euro year hen pressur
come currenc drop greater
bridg oper margin guid impli fx abat annual
synergi ramp particularli y/i addit sg leverag higher sale feel good acceler
revenu feel good get oper margin improv despit headw ind
paclitaxel panel doesnt go well still think time panel meet there much time
impact year doesnt go ell ould look busi expens structur manag
bd believ good data bd re-affirmed safeti profil product ith independ physician go
public process hile dcb headw ind leg peripher intervent busi intervent
busi overal dcb import stori
think growth someth achiev new number go give
guidanc deal model intact keep eye dcb momentum everyth talk offset
gore royalti place though royalti run bit higher thought ork tow ard get look
signific headw ind short term one ouldnt expect fx pressur next year dollar stay ould push
year flu normal dont headw ind resin spike gave guidanc last year got slightli favor
held oil price gone price resin suppli demand tariff remain seen level
headw ind year tend abat
dcb reduct impact margin high continu manufactur product low er volum
varianc good margin assumpt knee also come number
confid acceler number product launch expect progel back that
acceler expect md acceler base hypo demand see perform ell revenu synergi also
build havent seen much expect build confid revenu build ytd
 hich thought ould grow th impli back half hich feel comfort ith margin
fx impact fxn margin expect biggest driver ssg hich higher quarter hich
time impact comp benefit plan take tw compani differ year end normal
market commentari feel realli good posit infus pump continu gain share pt
pow er system pump integr pow er healthsight leverag data around
solut like dispens compound deal close today pump includ multipl element
emerg market perform see strong perform china see strong across three busi segment
fund healthcar system improv time
diabet swatch got feedback fda evalu option technic pathw ay simpl
longer term think ill take anoth quarter determin solut play
increment action taken increment fx impact alreadi drive strong underli grow th go
offset increment cut muscl dcb assum offset thing ent neg hich dont expect ould
take action off-set sale comp incent go take short term action hurt sale forc busi
track budget taken action hire freez manag indirect spend that drive base number
bard cost revenu synergi right track ith cost synergi recent achiev
infrastructur space suppli chain hen get ill look plant distribut revenu synergi
biosurgeri infect prevent europ invest heavili perform expect plan
invest agenda bard set forth fulli support bd exampl tva medic acquisit hich
go accord plan across three busi ell particularli emerg market china
surgeri side biosurgeri piec pro gel ramp perform arista powder reintroduc progel
oct/novemb pleas ith perform slightli ahead thought ould seen increas
competit hemostat side evalu eaten littl bit clinic perspect feel comfort ith
stand versu competitor enter market
back half comp much visibl visibl contract come variabl instal
placement confid ill momentum
kristen stew art cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens
 ill directli indirectli relat specif recommend view express research report
